Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Avacta Group plc ( (GB:AVCT) ) has shared an announcement.
Avacta Group plc has appointed Strand Hanson Limited as its Nominated Adviser with immediate effect, a key governance and regulatory role for companies listed on AIM, and confirmed that its issued share capital stands at 440,415,495 ordinary shares for the purposes of disclosure and transparency rules. The company also provided additional regulatory disclosures regarding past directorships of board member Richard Hughes in several companies that later entered administration, ensuring compliance with AIM Rule 17 and offering investors fuller visibility over the board’s historical corporate involvements.
The most recent analyst rating on (GB:AVCT) stock is a Hold with a £53.00 price target. To see the full list of analyst forecasts on Avacta Group plc stock, see the GB:AVCT Stock Forecast page.
Spark’s Take on GB:AVCT Stock
According to Spark, TipRanks’ AI Analyst, GB:AVCT is a Neutral.
Avacta Group plc’s overall stock score is primarily impacted by its weak financial performance and bearish technical indicators. While there is some progress in clinical programs, financial constraints and lack of partnerships remain significant risks. The stock’s valuation is unattractive due to negative earnings and no dividend yield.
To see Spark’s full report on GB:AVCT stock, click here.
More about Avacta Group plc
Avacta Therapeutics, a division of Avacta Group plc, is a clinical-stage life sciences company focused on oncology, developing its proprietary pre|CISION® tumor-activated drug delivery platform. The company’s pipeline includes pre|CISION® peptide drug conjugates and Affimer® drug conjugates designed to selectively release potent anticancer payloads in the tumor microenvironment by targeting fibroblast activation protein, aiming to improve efficacy while reducing systemic toxicity in patients with solid tumors.
Average Trading Volume: 2,750,046
Technical Sentiment Signal: Sell
Current Market Cap: £238.4M
For an in-depth examination of AVCT stock, go to TipRanks’ Overview page.